Cardiovascular · Clinical trials
Atrial Fibrillation Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About atrial fibrillation — and why its trials are hard
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, characterized by disorganized atrial electrical activity, irregular ventricular response and a substantially increased risk of thromboembolic stroke. Management rests on three pillars: stroke prevention with anticoagulation guided by CHA2DS2-VASc scoring, rate control, and rhythm control. The therapeutic landscape was transformed by the direct oral anticoagulants (DOACs), which replaced warfarin as first-line for most patients by offering fixed dosing, fewer interactions and no routine monitoring. Apixaban demonstrated superiority to warfarin in ARISTOTLE, and rivaroxaban established non-inferiority in ROCKET-AF; dabigatran (RE-LY) and edoxaban (ENGAGE AF-TIMI 48) complete the class. Rate control uses beta-blockers, non-dihydropyridine calcium-channel blockers and digoxin. Rhythm control employs antiarrhythmics such as amiodarone, flecainide and sotalol, with catheter ablation increasingly used, particularly since EAST-AFNET 4 supported early rhythm control. Historic anticoagulant development is littered with failures from bleeding and hepatotoxicity, underscoring the narrow therapeutic window of interfering with coagulation while protecting against stroke.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Apixaban (Eliquis) | 2012 | Stroke prevention in nonvalvular AF | ARISTOTLE | Stroke or systemic embolism | HR 0.79 vs warfarin (superiority); also reduced major bleeding (HR 0.69) and all-cause mortality (HR 0.89) |
| Rivaroxaban (Xarelto) | 2011 | Stroke prevention in nonvalvular AF | ROCKET-AF | Stroke or systemic embolism | Non-inferior to warfarin (HR ~0.88 on-treatment); similar major bleeding with less intracranial and fatal bleeding |
| Dabigatran (Pradaxa) | 2010 | Stroke prevention in nonvalvular AF | RE-LY | Stroke or systemic embolism | 150 mg dose superior to warfarin (RR ~0.66); 110 mg non-inferior with less bleeding |
| Edoxaban (Savaysa/Lixiana) | 2015 | Stroke prevention in nonvalvular AF | ENGAGE AF-TIMI 48 | Stroke or systemic embolism | Higher-dose non-inferior to warfarin (HR ~0.79-0.87) with significantly less major bleeding |
| Dronedarone (Multaq) | 2009 | Rhythm control in nonpermanent AF | ATHENA | First CV hospitalization or death | HR ~0.76 vs placebo; contraindicated in permanent AF and severe heart failure after PALLAS/ANDROMEDA harm signals |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in atrial fibrillation development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Ximelagatran — SPORTIF III/V | Met efficacy for stroke prevention but never approved in the US and withdrawn due to hepatotoxicity | Dose-dependent liver enzyme elevations created an unacceptable safety profile despite oral direct thrombin inhibition efficacy |
| Idraparinux — AMADEUS | Stopped early because of excess clinically relevant bleeding versus vitamin K antagonists | Long-acting factor Xa inhibitor with no reversal agent produced unacceptable bleeding despite non-inferior efficacy |
| Dronedarone (in permanent AF) — PALLAS | Terminated early for increased CV death, stroke and heart-failure hospitalization in permanent AF | Extending use beyond nonpermanent AF exposed higher-risk patients to net harm |
Choosing the right endpoint
Primary endpoints that matter in atrial fibrillation trials
- Stroke or systemic embolism — Primary efficacy endpoint in all pivotal DOAC AF trials
- Major bleeding (ISTH criteria) — Principal safety endpoint; intracranial hemorrhage is the most consequential component
- All-cause mortality — Key secondary; apixaban and dabigatran 150 mg showed mortality signals versus warfarin
- CV hospitalization — Composite used in rhythm-control trials such as ATHENA
How iNGENū runs atrial fibrillation trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Atrial Fibrillation clinical trials — FAQs
Why did DOACs replace warfarin?
Is rate or rhythm control better?
Which DOAC showed superiority over warfarin?
Ready to discuss your atrial fibrillation trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal